tanibirumab
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01660360)
Timeline
Indications
Mechanism of action
Vascular endothelial growth factor receptor 2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298119 ↗
Also known as
- tanibirumab
- tanibirumab
- ttac-0001
- ttac-0001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04751955 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2022 | Seoul National University |
| NCT04986852 | Phase 2 | Aug 30, 2021 | Merck, PharmAbcine |
| NCT03033524 | Phase 2 | Feb 1, 2016 | PharmAbcine |
| NCT01660360 | Phase 1 | Nov 1, 2011 | PharmAbcine, Sungkyunkwan University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PharmAbcine | For profit | 3 | 3 | 2 | 2011 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1